CA Patent

CA2802042A1 — Crystalline forms of kinase inhibitors

Assigned to AbbVie Bahamas Ltd · Expires 2011-12-15 · 14y expired

What this patent protects

Salts of N-(4- {4-amino-7-[ 1 -(2-hydroxyethyl)- 1 H-pyrazol-4-yl]thieno[3,2-c]pyridin- 3-yl}phenyl)-N'-(3-fluorophenyl)urea and crystalline forms thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, canc…

USPTO Abstract

Salts of N-(4- {4-amino-7-[ 1 -(2-hydroxyethyl)- 1 H-pyrazol-4-yl]thieno[3,2-c]pyridin- 3-yl}phenyl)-N'-(3-fluorophenyl)urea and crystalline forms thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.

Drugs covered by this patent

Patent Metadata

Patent number
CA2802042A1
Jurisdiction
CA
Classification
—
Expires
2011-12-15
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Bahamas Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.